Key Highlights

  • Viking Therapeutics shares closed at $36.75 today, down 11.76%, giving back most of Tuesday's 36% surge.
  • The company priced an upsized $500 million financing package, including 7.86 million shares at $35 per share, a discount to Wednesday's close.
  • The offering also includes $225 million in 2% convertible notes due 2032.
  • The raise is intended to fund continued development of VK2735 and VK3019, though the dilution is overshadowing recent clinical progress on strong VK2735 maintenance-dosing data.

Shares Give Back Most of Tuesday's Rally

Viking Therapeutics (NASDAQ:VKTX) shares closed sharply lower today, giving back most of Tuesday's 36% surge after the company priced an upsized $500 million financing package. The package includes 7.86 million shares of common stock priced at $35 per share, a discount to Wednesday's close, plus $225 million in 2% convertible senior notes due 2032, just two days after the company reported strong VK2735 maintenance-dosing data.

Dilution Concerns Overshadow Strong Clinical Data

Investors are weighing dilution concerns against the encouraging obesity-drug results, which showed up to 97% weight-loss retention with less-frequent dosing and had drawn bullish analyst commentary from multiple research firms earlier in the week. The raise, intended to fund continued VK2735 and VK3019 development, is overshadowing the clinical progress and pressuring the stock toward its worst session in over a year, compounded by a broader risk-off tone as Treasury yields surge to multi-decade highs.

A Well-Capitalized but Pre-Revenue Obesity Drug Developer

Viking Therapeutics is a San Diego-based clinical-stage biopharmaceutical company focused on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Its lead pipeline asset, VK2735, is a dual agonist of the GLP-1 and GIP receptors being developed in both subcutaneous and oral formulations for obesity and related metabolic disease, complemented by VK2809, a liver-selective thyroid hormone receptor Beta agonist for NASH and NAFLD, and other programs including VK0214 for X-linked adrenoleukodystrophy.